(Q38908481)

7 September 2017

Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice (English)

1 reference

7 September 2017

Plasmodium falciparum

0 references

Ali Jafarshad

2

0 references

Pierre Druilhe

7

object named as

Pierre Druilhe

1 reference

7 September 2017

9

Giampietro Corradin

1 reference

7 September 2017

3

Catherine Servis

1 reference

7 September 2017

Saidou Balam

1

1 reference

7 September 2017

Geraldine Frank

4

1 reference

7 September 2017

Steve Reed

5

1 reference

7 September 2017

Richard Pink

6

1 reference

7 September 2017

François Spertini

8

1 reference

7 September 2017

language of work or name

English

0 references

publication date

10 February 2016

1 reference

7 September 2017

1 reference

7 September 2017

34

1 reference

7 September 2017

13

1 reference

7 September 2017

1566-1574

1 reference

Plasmodium falciparum merozoite surface protein 2: epitope mapping and fine specificity of human antibody response against non-polymorphic domains

7 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Selection of an adjuvant for vaccination with the malaria antigen, MSA-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4+ T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Adjuvant activity of CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

A synthetic adjuvant to enhance and expand immune responses to influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Strain-specific humoral response to a polymorphic malaria vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Targeting TLRs expands the antibody repertoire in response to a malaria vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.013

10.1016/J.VACCINE.2016.02.013

7 January 2021

Identifiers

DOI

1 reference

7 September 2017

1 reference